Grifols (NASDAQ:GRFS) Shares Gap Up – Time to Buy?

Grifols, S.A. (NASDAQ:GRFS)’s share price gapped up prior to trading on Wednesday . The stock had previously closed at $6.96, but opened at $7.22. Grifols shares last traded at $7.15, with a volume of 437,796 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley started coverage on Grifols in a research note on Wednesday, February 12th. They set an “overweight” rating for the company.

Grifols Price Performance

The firm has a market capitalization of $4.95 billion, a P/E ratio of 6.16 and a beta of 0.35. The business’s fifty day moving average is $7.55 and its 200 day moving average is $8.01. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11.

Hedge Funds Weigh In On Grifols

Hedge funds and other institutional investors have recently modified their holdings of the stock. R Squared Ltd purchased a new stake in shares of Grifols in the 4th quarter valued at approximately $28,000. GAMMA Investing LLC boosted its position in shares of Grifols by 44.5% in the fourth quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company’s stock worth $37,000 after buying an additional 1,527 shares during the period. Blue Trust Inc. grew its holdings in shares of Grifols by 254.0% during the fourth quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 4,970 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Grifols by 354.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company’s stock valued at $60,000 after buying an additional 6,335 shares in the last quarter. Finally, First Trust Advisors LP acquired a new position in Grifols during the fourth quarter valued at $75,000.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.